All In Biotech

Drug Trial Radar · NCT02096601

A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

A Multicenter, Open-Label, Randomized, Dose-Finding Study Testing the Safety, Tolerability, and Pharmacokinetics (PK) of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD) Delivered as a Continuous Subcutaneous Infusion (SC) in Parkinson's Disease (PD) Patients Treated With LD

Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Aug 11, 2014

Primary completion

Mar 15, 2015

Study completion Mar 15, 2015

Sponsor

Lead sponsor
NeuroDerm Ltd.Industry
Sponsor type
Industry
Collaborators
Michael J. Fox Foundation for Parkinson's Research
First posted
Mar 26, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label randomized study to evaluate the Safety, Tolerability, and PK of Low and High single doses of ND0612 (i.e. LD/CD ratio 60/7.5 mg/mL and 60/14 mg/mL), as well as the combination with oral Entacapone (concomitant catechol-O-methyl transferase \[COMT\] inhibitor) in PD subjects with well-defined morning "OFF" and a good response to LD. Exploratory efficacy parameters were collected (early evidence of effectiveness as part of Phase 1).

Conditions

  • Parkinson's Disease

Interventions

  • LD/CD SC solutionDrug

    Levodopa/carbidopa SC solution

  • EntacaponeDrug

    Entacapone 200 mg oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events frequencyTime frame: Up to 6 weeks
  2. LD, CD and 3-OMD PK analysis from sample taken on Days 3, 4 and 5 will be used to determine the Fluctuation Index, its CV, AUC, Cmin, Cmax, and tmax.Time frame: Days 1, 2, 3 and 4
  3. Tolerability: Number of patients who discontinued due to adverse eventsTime frame: Up to 6 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hadassah Medical Center

    Jerusalem, Israel

  • Tel Aviv Medical Center

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.